FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2165172921> ?p ?o ?g. }

• W2165172921 endingPage "810" @default.
• W2165172921 startingPage "802" @default.
• W2165172921 abstract "OBJECTIVE: To review the in vitro receptor binding data of calcium-channel blockers (CCBs) and in vivo studies in humans regarding the use of dual calcium-channel blocker therapy, with a focus on the use of this therapy for hypertens DATA SOURCE: A MEDLINE search was conducted to identify literature pertaining to CCBs. STUDY SELECTION: In vitro studies and investigations that evaluated CCB receptor binding and the interactions between subclasses of CCBs were chosen. All studies in humans and clinical trials that evaluated the use of dual CCB therapy in the treatment of cardiovascular diseases were selected for review. Also, case reports describing the use of dual CCB therapy were included in this article. DATA EXTRACTION: The methodology, results, and conclusions of the selected data were evaluated. Data regarding the in vitro receptor binding kinetics of CCBs, as well as interactions, were reported. Because there is limited information on dual CCB therapy for hypertension, clinical studies using this treatment for ischemic heart disease were also reviewed. They were summarized and compared on the basis of the degree of disease control (e.g., blood pressure, exercise tolerance), adverse effects, and other clinical endpoints of pharmacologic therapy. DATA SYNTHESIS: In vitro studies have identified binding sites for the dihydropyridine (nifedipine), diphenylalkylamine (verapamil), and benzothiazepine (diltiazem) subclasses of CCBs, and indicate that they are allosterically related to each other within the voltage-sensitive calcium-channel receptor. Dihydropyridine binding affinity is decreased with concomitant verapamil binding, but is enhanced by concomitant diltiazem binding. Dual CCB therapy has been shown to be efficacious in patients with ischemic heart disease. Although this therapy is limited by dose-related adverse effects, it appears to have an important role in patients with ischemia that is refractory to conventional therapy, or for those whose therapeutic options are limited by contraindications. Theoretically, many patients with hypertension may benefit similarly from dual CCB therapy. Because data evaluating this treatment option are sparse, recommendations regarding safety, efficacy, and the role of dual CCB therapy for hypertension would be premature. CONCLUSIONS: Controlled data evaluating dual CCB therapy for the treatment of hypertension are lacking. This treatment modality may be beneficial in the future, but requires further investigation to determine safety and efficacy." @default.
• W2165172921 created "2016-06-24" @default.
• W2165172921 creator A5035229665 @default.
• W2165172921 creator A5051099314 @default.
• W2165172921 date "1996-07-01" @default.
• W2165172921 modified "2023-09-25" @default.
• W2165172921 title "Dual Calcium-Channel Blocker Therapy in the Treatment of Hypertension" @default.
• W2165172921 cites W1575818929 @default.
• W2165172921 cites W1972567428 @default.
• W2165172921 cites W1980936571 @default.
• W2165172921 cites W1983391267 @default.
• W2165172921 cites W1990177715 @default.
• W2165172921 cites W1991516364 @default.
• W2165172921 cites W1993660067 @default.
• W2165172921 cites W1998104311 @default.
• W2165172921 cites W2001659679 @default.
• W2165172921 cites W2002825025 @default.
• W2165172921 cites W2006192148 @default.
• W2165172921 cites W2008205096 @default.
• W2165172921 cites W2011910735 @default.
• W2165172921 cites W2012988898 @default.
• W2165172921 cites W2031297190 @default.
• W2165172921 cites W2033195198 @default.
• W2165172921 cites W2049907486 @default.
• W2165172921 cites W2058645062 @default.
• W2165172921 cites W2061228453 @default.
• W2165172921 cites W2067074491 @default.
• W2165172921 cites W2077004730 @default.
• W2165172921 cites W2079737282 @default.
• W2165172921 cites W2083866023 @default.
• W2165172921 cites W2089207234 @default.
• W2165172921 cites W2090906745 @default.
• W2165172921 cites W2092805838 @default.
• W2165172921 cites W2093977794 @default.
• W2165172921 cites W2094028715 @default.
• W2165172921 cites W2106073810 @default.
• W2165172921 cites W2134270369 @default.
• W2165172921 cites W2139480984 @default.
• W2165172921 cites W2141470258 @default.
• W2165172921 cites W2149561964 @default.
• W2165172921 cites W2170716254 @default.
• W2165172921 cites W2312342110 @default.
• W2165172921 cites W2318174853 @default.
• W2165172921 cites W2566199751 @default.
• W2165172921 cites W2586339097 @default.
• W2165172921 cites W3144480914 @default.
• W2165172921 cites W4230706082 @default.
• W2165172921 cites W4242459468 @default.
• W2165172921 cites W4248289089 @default.
• W2165172921 cites W4248451318 @default.
• W2165172921 doi "https://doi.org/10.1177/106002809603000719" @default.
• W2165172921 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8826565" @default.
• W2165172921 hasPublicationYear "1996" @default.
• W2165172921 type Work @default.
• W2165172921 sameAs 2165172921 @default.
• W2165172921 citedByCount "6" @default.
• W2165172921 countsByYear W21651729212012 @default.
• W2165172921 countsByYear W21651729212017 @default.
• W2165172921 crossrefType "journal-article" @default.
• W2165172921 hasAuthorship W2165172921A5035229665 @default.
• W2165172921 hasAuthorship W2165172921A5051099314 @default.
• W2165172921 hasConcept C126322002 @default.
• W2165172921 hasConcept C2776741139 @default.
• W2165172921 hasConcept C2776999253 @default.
• W2165172921 hasConcept C2777022698 @default.
• W2165172921 hasConcept C2779066535 @default.
• W2165172921 hasConcept C2780356492 @default.
• W2165172921 hasConcept C2781212610 @default.
• W2165172921 hasConcept C519063684 @default.
• W2165172921 hasConcept C71924100 @default.
• W2165172921 hasConcept C84393581 @default.
• W2165172921 hasConcept C85520022 @default.
• W2165172921 hasConcept C98274493 @default.
• W2165172921 hasConceptScore W2165172921C126322002 @default.
• W2165172921 hasConceptScore W2165172921C2776741139 @default.
• W2165172921 hasConceptScore W2165172921C2776999253 @default.
• W2165172921 hasConceptScore W2165172921C2777022698 @default.
• W2165172921 hasConceptScore W2165172921C2779066535 @default.
• W2165172921 hasConceptScore W2165172921C2780356492 @default.
• W2165172921 hasConceptScore W2165172921C2781212610 @default.
• W2165172921 hasConceptScore W2165172921C519063684 @default.
• W2165172921 hasConceptScore W2165172921C71924100 @default.
• W2165172921 hasConceptScore W2165172921C84393581 @default.
• W2165172921 hasConceptScore W2165172921C85520022 @default.
• W2165172921 hasConceptScore W2165172921C98274493 @default.
• W2165172921 hasIssue "7-8" @default.
• W2165172921 hasLocation W21651729211 @default.
• W2165172921 hasLocation W21651729212 @default.
• W2165172921 hasOpenAccess W2165172921 @default.
• W2165172921 hasPrimaryLocation W21651729211 @default.
• W2165172921 hasRelatedWork W179011299 @default.
• W2165172921 hasRelatedWork W17926688 @default.
• W2165172921 hasRelatedWork W1972225279 @default.
• W2165172921 hasRelatedWork W2039661997 @default.
• W2165172921 hasRelatedWork W2056647123 @default.
• W2165172921 hasRelatedWork W2062950741 @default.
• W2165172921 hasRelatedWork W2148282970 @default.
• W2165172921 hasRelatedWork W2282016799 @default.

• next